- Home
- PRPL vs IMUX Comparison
PRPL vs IMUX Comparison
Compare PRPL & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPL
- IMUX
- Stock Information
- Founded
- PRPL 2010
- IMUX 2016
- Country
- PRPL United States
- IMUX United States
- Employees
- PRPL N/A
- IMUX N/A
- Industry
- PRPL Home Furnishings
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- PRPL Consumer Discretionary
- IMUX Health Care
- Exchange
- PRPL Nasdaq
- IMUX Nasdaq
- Market Cap
- PRPL 125.6M
- IMUX 90.4M
- IPO Year
- PRPL N/A
- IMUX N/A
- Fundamental
- Price
- PRPL $1.07
- IMUX $0.85
- Analyst Decision
- PRPL Hold
- IMUX Strong Buy
- Analyst Count
- PRPL 1
- IMUX 5
- Target Price
- PRPL $1.00
- IMUX $7.50
- AVG Volume (30 Days)
- PRPL 525.4K
- IMUX 1.3M
- Earning Date
- PRPL 11-03-2025
- IMUX 11-06-2025
- Dividend Yield
- PRPL N/A
- IMUX N/A
- EPS Growth
- PRPL N/A
- IMUX N/A
- EPS
- PRPL N/A
- IMUX N/A
- Revenue
- PRPL $456,844,000.00
- IMUX N/A
- Revenue This Year
- PRPL N/A
- IMUX N/A
- Revenue Next Year
- PRPL $11.87
- IMUX N/A
- P/E Ratio
- PRPL N/A
- IMUX N/A
- Revenue Growth
- PRPL N/A
- IMUX N/A
- 52 Week Low
- PRPL $0.56
- IMUX $0.56
- 52 Week High
- PRPL $1.29
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- PRPL 55.23
- IMUX 49.36
- Support Level
- PRPL $1.01
- IMUX $0.75
- Resistance Level
- PRPL $1.13
- IMUX $0.90
- Average True Range (ATR)
- PRPL 0.06
- IMUX 0.06
- MACD
- PRPL -0.01
- IMUX 0.00
- Stochastic Oscillator
- PRPL 41.67
- IMUX 65.16
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms and other products. The Company has one reportable segment that operates an omni-channel distribution which allows the Company to offer a seamless shopping experience to its customers across multiple sales channels. It sells its products through its direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.